Literature DB >> 1107601

Carcinoembryonic antigen and bladder carcinoma.

G Ionescu, N A Romas, L Ionascu, S Bennett, M Tannenbaum, R J Veeneman, J K Lattimer.   

Abstract

The 24-hour urinary carcinoembryonic antigen determinations were performed on 61 patients with different stages of bladder carcinoma. Elevated titers were found in 81 per cent of the patients with active tumors and falsely positive studies were found in 7 per cent. High stage lesions were found to have high carcinoembryonic antigen levels. Plasma carcinoembryonic antigen determinations were elevated in only 45 per cent of the patients with active tumors but further study may be warranted in advanced bladder cancer cases. The 24-hour urinary carcinoembryonic antigen measurements yield the highest percentage elevations in bladder carcinoma and further investigation is required to better define its clinical application.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1107601     DOI: 10.1016/s0022-5347(17)59061-8

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

1.  Immunohistochemical demonstration of tumor-associated antigens with the aid of monoclonal and polyclonal antisera in carcinoma of the bladder.

Authors:  J Steffens; W Friedmann; H Lobeck
Journal:  Urol Res       Date:  1985

2.  The significance of serum lipid-bound sialic acid in bladder tumours.

Authors:  A Oztokatli; H Ozkardeş; E Ovül; D Erol
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

3.  Carcinoembryonic antigen (CEA) levels in patients with brain tumours.

Authors:  E Miyake; M Yamashita; K Kitamura; F Ishigami
Journal:  Acta Neurochir (Wien)       Date:  1979       Impact factor: 2.216

4.  Urine carcinoembryonic antigen levels are more useful than serum levels for early detection of Bilharzial and non-Bilharzial urinary bladder carcinoma: observations of 43 Egyptian cases.

Authors:  Gamal M Saied; Wafaa H El-Metenawy; Mohamed S Elwan; Nazar R Dessouki
Journal:  World J Surg Oncol       Date:  2007-01-15       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.